Literature DB >> 17060860

Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery?

Andres Beiras-Fernandez1, Florian C Weis, Herbert Fuchs, Bruno M Meiser, Bruno Reichart, Marion Weis.   

Abstract

Heart transplantation is considered nowadays the gold standard in the therapy of chronic and terminal heart insufficiency. Primary organ failure after heart transplantation is a severe complication generally related to prolonged ischemia time, poor quality of the organ, or acute rejection. All these factors can potentially lead to multiorgan failure. Pharmacological and mechanical support for these patients is limited and often related to side effects. Ca sensitizers have been proposed to increase cardiac contractility without altering intracellular Ca levels, thus avoiding the side effects of Ca overload. We report two cases of heart transplanted patients suffering from acute graft failure in the early postoperative period who recovered after intravenous administration of levosimendan, a Ca sensitizer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060860     DOI: 10.1097/01.tp.0000233845.15508.89

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation.

Authors:  Stjepan Barisin; Viktor Djuzel; Ana Barisin; Igor Rudez
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 2.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Primary graft failure after heart transplantation.

Authors:  Arjun Iyer; Gayathri Kumarasinghe; Mark Hicks; Alasdair Watson; Ling Gao; Aoife Doyle; Anne Keogh; Eugene Kotlyar; Christopher Hayward; Kumud Dhital; Emily Granger; Paul Jansz; Roger Pye; Phillip Spratt; Peter Simon Macdonald
Journal:  J Transplant       Date:  2011-08-01

4.  Levosimendan protects human hepatocytes from ischemia-reperfusion injury.

Authors:  Stefanie N Brunner; Nicolai V Bogert; Andreas A Schnitzbauer; Eva Juengel; Anton Moritz; Isabella Werner; Angela Kornberger; Andres Beiras-Fernandez
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

5.  Levosimendan as rescue therapy in low output syndrome after cardiac surgery: effects and predictors of outcome.

Authors:  Andres Beiras-Fernandez; Angela Kornberger; Martin Oberhoffer; Felix Kur; Marion Weis; Christian-Friedrich Vahl; Florian Weis
Journal:  J Int Med Res       Date:  2019-03-26       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.